Table 5. Combination therapy performed for enrolled patients with SFTS.
| Treatment categories | Overall (n = 23) | Groups | p-Value* | |
|---|---|---|---|---|
| Fatal (n = 4) | Non-fatal (n = 19) | |||
| Corticosteroids | 11 (48%) | 3 (75%) | 8 (42%) | 0.32 |
| Steroid pulse therapy | 8 (35%) | 2 (50%) | 6 (32%) | 0.59 |
| Antimicrobial agents | ||||
| Quinolone | 10 (43%) | 1 (25%) | 9 (47%) | 0.6 |
| Tetracycline | 5 (22%) | 1 (25%) | 4 (21%) | 1.00 |
| Glycopeptide | 2 (9%) | 0 (0%) | 2 (11%) | 1.00 |
| Other | 1 (4%) | 0 (0%) | 1 (5%) | 1.00 |
| Candin | 6 (26%) | 0 (0%) | 6 (32%) | 0.54 |
| Blood products transfused | ||||
| Platelets | 8 (35%) | 3 (75%) | 5 (26%) | 0.10 |
| Red blood cells | 2 (9%) | 1 (25%) | 1 (5%) | 0.32 |
| Fresh frozen plasma | 2 (9%) | 0 (0%) | 2 (11%) | 1.00 |
| Immunoglobulin | 4 (17%) | 1 (25%) | 3 (16%) | 1.00 |
| Thrombomodulin | 3 (13%) | 1 (25%) | 2 (11%) | 0.45 |
| Blood purification therapy | 3 (13%) | 1 (25%) | 2 (11%) | 0.45 |
| Mechanical ventilation | 6 (26%) | 3 (75%) | 3 (16%) | 0.04 |
* Fisher’s exact test.